Online Program

Acting on what we know about SUID: Using the Child Death Review Process to improve SUID investigations and create SUID prevention efforts in communities and states

Monday, November 4, 2013 : 12:30 p.m. - 12:50 p.m.

Theresa Covington, MPH, National Center for the Review & Prevention of Child Deaths, Michigan Public Health Institute, Washington, DC
The CDC's SUID Case Registry using child death review teams and an expanded version of the National Child Death Review (CDR) Case Reporting system to collect comprehensive data on sudden and unexplained infant deaths in nine states. The CDR process is proving effective in not only improving the collection of data from multiple sources on SUID circumstances, but in catalyzing local and state actions across the spectrum of investigation, diagnosis, services and prevention. Every state in the US has local and/or state level reviews and most include both MCH and state injury prevention partners at the reviews. This session will describe examples of Child Death Review teams that have catalyzed significant changes in communities related to sudden and unexpected infant deaths.

Learning Areas:

Implementation of health education strategies, interventions and programs
Planning of health education strategies, interventions, and programs

Learning Objectives:
Describe at least 8 elements necessary for an effective infant SUID death case review. List at least three SUID outcomes from an effective case review. Identify action steps to take in their own communities to improve their child death review.

Keyword(s): SIDS

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have been the Executive Director of the National Center for the Review and Prevention of Child Death for more than 15 years. Previous to this appointment, I served as the founder and director of the Michigan Child Death Review program.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.